Tag: ASH16

ash16_650x450
January 18, 2017/Research

ASH 2016 Top 10 Abstracts

Hard hitters that caught our attention

ash16_650x450
December 6, 2016/Research

Pacritinib Outperforms Best Available Therapy for Myelofibrosis

Investigators working with FDA on safety signal

ash16_650x450
December 5, 2016/Research

Vadastuximab for AML: Investigator Predicts Changes to Standard Therapy in Near Future

Drug targets CD33 to produce high remission rates

ash16_650x450
December 4, 2016/Research

Study: Eltrombopag May Help Hasten Platelet Recovery in Acute Myeloid Leukemia

Interim analysis signals efficacy in older patients

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

ash16_650x450
December 4, 2016/Research

Study Identifies Predictors of Bleeding in Hospitalized Cancer Patients

Findings may help guide risk-adapted thromboprophylaxis

ash16_650x450
December 3, 2016/Research

Study Examines Pain and Quality of Life in Hemophilia Patients

Findings may help individualize care and optimize patient well-being.

ash16_650x450
December 3, 2016/Research

Pomalidomide Tames Refractory Bleeding in Rare Hemorrhagic Disorder

Cleveland Clinic’s pilot study signals efficacy in HHT

Dr.-Sauntharajah_650x450
December 3, 2016/Research

Novel Drug Regimen Shows Promise for Sickle Cell Disease

Trial results reported for first molecularly targeted therapy

ash16_650x450
November 30, 2016/Research

ASH 2016 – Saturday, December 3

Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting

ash16_650x450
November 29, 2016/Research

ASH 2016 – Sunday, December 4

Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting

BackPage 1 of 2Next
Advertisement
Ad